Syapse Stock
Real-World Evidence Company
Sign up today and learn more about Syapse Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Syapse Stock
Syapse works with health systems to implement precision medicine programs across their organizations, enabling oncologists to deliver personalized care to every patient who needs it.
Investors
Social Capital
Relativity Space, Slack, Netskope, Box, BetterUp, Greenlight, Guild Education, Flutterwave, Palmetto Clean Technology, Groq
Social Capital Partners
Ascension Ventures
Funding History
January 2011 | $1.6M |
---|---|
January 2013 | $3.0M |
July 2014 | $10.0M |
January 2016 | $25.0M |
November 2017 | $30.0M |
January 2019 | $20.0M |
May 2020 | $30.0M |
Management
Chief Executive Officer
Ken Tarkoff
Chief Financial Officer
Fletcher Payne
Chief Technology Officer
Tony Loeser
Press
clinicaltrialsarena - Feb, 23 2024
Signal: FDA renews Syapse collaboration to use real-world data in oncologyglobenewswire - Dec, 7 2023
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncologybiospace - Sep, 16 2022
Syapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand Cancersbiospace - Aug, 18 2022
Science 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trialsfinsmes - Jul, 28 2022
Syapse Raises $35M in Growth Funding